Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 9:9:846470.
doi: 10.3389/fsurg.2022.846470. eCollection 2022.

Correlation of Serum CysC, IMA, and LP-PLA2 Levels With Type 2 Diabetes Mellitus Patients With Lower Extremity Atherosclerotic Occlusive Disease

Fen Feng  1 , Yong Chen  2 , Gang Wang  3 , Ping Huang  3 , Qiaolin Zhu  3 , Bin Zhou  3
Affiliations

Correlation of Serum CysC, IMA, and LP-PLA2 Levels With Type 2 Diabetes Mellitus Patients With Lower Extremity Atherosclerotic Occlusive Disease

Fen Feng et al. Front Surg. .

Abstract

Objective: To investigate the serum level of cystatin C (CysC), ischemia-modified albumin (IMA), and lipoprotein-associated phospholipase A2 (LP-PLA2) in patients with type 2 diabetes mellitus (T2DM) and with lower extremity atherosclerotic occlusive disease (LEASOD) and their correlation.

Methods: From March 2017 to December 2019, 110 patients with T2DM with LEASOD, who were treated in our hospital, were selected as the observation group. One hundred ten healthy persons who received medical examination in our hospital during the same period were selected as the control group. Serum CysC, IMA, LP-PLA2, and ankle-brachial index (ABI) were detected in each group. According to the ABI index, the observation group was divided into three subgroups, namely, the mild group (n = 45), the moderate group (n = 42), and the severe group (n = 23). Pearson correlation analysis was used to analyze the relationship between serum CysC, IMA, and LP-PLA2 levels in patients with T2DM with LEASOD and their condition. The receiver operator characteristic (ROC) curve was used to analyze the diagnostic value of serum CysC, IMA, and LP-PLA2 levels in patients with T2DM with LEASOD.

Results: The serum levels of CysC, IMA, and LP-PLA2 in the observation group were higher than those in the control group (p < 0.05). The serum levels of CysC, IMA, and LP-PLA2 in the severe and the moderate group were higher than those in the mild group, and the serum levels of CysC, IMA, and LP-PLA2 in the severe group were higher than those in the moderate group (p < 0.05). Pearson correlation analysis showed that CysC, IMA, and LP-PLA2 levels were all negatively correlated with ABI (r = -0.802, r = -0.757, r = -0.764, p < 0.001). The ROC curve results showed that the area under the curve (AUC) of serum CysC in the diagnosis of T2DM with LEASOD was 0.806, and the best cut-off value was 1.74 mg/L. The AUC of serum IMA for diagnosis of T2DM with LEASOD was 0.772, and the best cut-off value was 92.58 g/L. The AUC of serum LP-PLA2 in the diagnosis of T2DM with LEASOD was 0.781, and the best cut-off value was 544.86 ng/L. The AUC of the three combined diagnoses of T2DM with LEASOD was 0.863.

Conclusion: Serum levels of CysC, IMA, and LP-PLA2 were increased in patients with T2DM with LEASOD. Serum CysC, IMA, and LP-PLA2 are closely related to the severity of the disease. The higher the serum levels of CysC, IMA, and LP-PLA2, the more serious the degree of lower extremity arteriosclerosis occlusion, which can be used as an important serum marker to monitor the severity of T2DM with LEASOD. The combined detection of serum CysC, IMA, and LP-PLA2 has good diagnostic value for patients with T2DM with LEASOD.

Keywords: correlation; cystatin C; ischemia modified albumin; lipoprotein phospholipase A2; lower extremity atherosclerotic occlusive disease; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Comparison of serum cystatin C (CysC), ischemia modified albumin (IMA), and lipoprotein phospholipase A2 (LP-PLA2) levels between the two groups. Compared with the control group, *p < 0.05.
Figure 2
Figure 2
Comparison of serum CysC, IMA, and LP-PLA2 levels among different subgroups in the observation group. Compared with the mild group, *p < 0.05; compared with the moderate group, #p < 0.05.
Figure 3
Figure 3
Correlation between serum CysC, IMA, and LP-PLA2 levels and the severity of the disease in the observation group.
Figure 4
Figure 4
Receiver operator characteristic (ROC) curve of serum CysC, IMA, and LP-PLA2 for the diagnosis of patients with T2DM with LEASOD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sen S, Chakraborty R. Treatment and diagnosis of diabetes mellitus and its complication: advanced approaches. Mini Rev Med Chem. (2015) 15:1132–3. 10.2174/138955751514151006154616 - DOI - PubMed
    1. Dos S M M, Castellsague M, Perrenoud L, Coppin G, Gastaldi G. Diabetes mellitus: impact of affects on self-management skills. Rev Med Suisse. (2020) 16:1206–9. - PubMed
    1. Shen C, Li W. Interpretation and consideration of the Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Chin J Surg. (2016) 54:81–3. 10.3760/cma.j.issn.0529-5815.2016.02.001 - DOI - PubMed
    1. Cai H, Fu F, Wang Y, Li J, Cao J, Huang M, et al. . Correlation between the stenosis degree of aorto-iliac artery and superior mesenteric artery in patients with lower extremity atherosclerotic occlusive disease by CT angiography. Chin Crit Care Med. (2018) 30:635–9. 10.3760/cma.j.issn.2095-4352.2018.07.004 - DOI - PubMed
    1. Dionyssiou-Asteriou A, Papastamatiou M, Vatalas I, Bastounis E. Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities. Eur J Vasc Endovasc Surg. (2000) 20:57–60. 10.1053/ejvs.2000.1100 - DOI - PubMed